Rosai-Dorfman DiseasePhase 2NCT04924647
Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
A Phase 2 study testing lenalidomide and dexamethasone in people with Rosai-Dorfman Disease, run by Peking Union Medical College Hospital at 1 site in China.
Trial summary
Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is mostly based on retrospective study. Steroid was suggested as frontline treatment as RDD with only lymph nodes involvement. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Rosai-Dorfman Disease
- What is being tested?
- lenalidomide and dexamethasone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteChina
- Study dates
- 8 Jun 2021to 31 Dec 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed diagnosis of RDD
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Patients must have adequate renal, liver, and bone marrow function as defined by the following criteria:
- Absolute neutrophil count ≥1500 cells per mm3 Platelet count ≥100000 cells per mm3 Creatinine clearance [according to Cockcroft formula] ≥60 mL/min. Aspartate aminotransferase and alanine aminotransferase ≤2·5×upper limit of normal [ULN], and total bilirubin ≤2·5×ULN; or ≤10×ULN in the case of known liver involvement by RDD.
- No active or untreated infection.
Show all 13Show fewer
- No cardiac abnormalities.
- Subject provide written informed consent.
- A female is eligible to enter and participate in this study if she is of:
- Non-childbearing potential including ω Any female who has had a surgical procedure rendering her incapable of becoming pregnant.
- ω Subjects have experienced total cessation of menses for more than 1 year and be greater than 45 years in age.
- ⎫ Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, and agrees to use adequate contraception.
- Male subjects must use an effective barrier method of contraception during the study and for 90 days following the last course of MA if sexually active with a childbearing potential
Who cannot join
- Patients had concurrent malignancies.
- History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.
- Women who were pregnant or of childbearing potential.
- Known HIV seropositive, active hepatitis C infection, and/or hepatitis B (defined as HCV RNA≥1000 copies or HBV DNA ≥1000 copies at screening).
- Major surgical procedure within 28 days prior to the first dose of study treatment.
- Presence of uncontrolled infection.
- Evidence of active bleeding or bleeding diathesis.
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Peking Union Medical College Hospital
Beijing
Xinxin Cao
About this study
Official title: Lenalidomide and Dexamethasone for Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study
Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is mostly based on retrospective study. Steroid was suggested as frontline treatment as RDD with only lymph nodes involvement. Studies showed thalidomide or lenalidomide showed some effect in recurrent/refractory skin RDD. The investigators want to analyze the efficacy and toxicity of lenalidomide combined with dexamethasone regimens in the treatment of RDD among adult patients at our hospital.
- Conditions
- Rosai-Dorfman Disease
- Being tested
- lenalidomide and dexamethasone
- Keywords
- Rosai-Dorfman Disease, lenalidomide, dexamethasone
- Medical subject headings
- Histiocytosis, Sinus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
lenalidomide and dexamethasoneDrug
lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
| Study group | Role | What they receive |
|---|---|---|
| RD | Experimental | lenalidomide and dexamethasone Receives: Drug: lenalidomide and dexamethasone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Event-free survival
Events were defined as a poor response to RD, reactivation after RD therapy and death from any cause.
Measured: the duration from initiation of treatment to the date of first documented event or date of death from any cause, whichever come first, assessed up to 5 years
Secondary outcomes (2)
Overall response rate
the cumulative number of patients with either non-active disease or regressive disease (signs and symptoms were improved with no new lesions) after RD
Measured: on 12 months
Overall survival
Measured: the duration from initiation of RD treatment to the date of death or last follow-up, assessed up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2021
- Study start8 Jun 2021
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rosai-Dorfman DiseaseStudies of the same condition, open and under way.
- More trials run by Peking Union Medical College HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking Union Medical College Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cao Xinxin, Peking Union Medical College Hospital
- Investigators
- Dao-bin Zhou, Study chair, Peking Union Medical College Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04924647
- Sponsor's protocol ID
- PUMCHRDD1
- Status last verified
- Jun 2021
- First submitted
- 7 Jun 2021
- Last updated
- 16 Jun 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chang L, Lang M, Liu T, Lin H, Liu ZZ, Cai H, Zhou DB, Cao XX. Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study. EClinicalMedicine. 2024 Jun 21;73:102685. doi: 10.1016/j.eclinm.2024.102685. eCollection 2024 Jul.
PubMed 39022796
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lenalidomide and Dexamethasone for Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study
- ClinicalTrials.gov ID
- NCT04924647
- Acronym / sponsor ID
- PUMCHRDD1
- Conditions
- Rosai-Dorfman Disease
- Keywords
- Rosai-Dorfman Disease, lenalidomide, dexamethasone
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- Peking Union Medical College HospitalUniversity, hospital or other
- Study start
- 8 Jun 2021 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 14 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is mostly based on retrospective study. Steroid was suggested as frontline treatment as RDD with only lymph nodes involvement. Studies showed thalidomide or lenalidomide showed some effect in recurrent/refractory skin RDD. The investigators want to analyze the efficacy and toxicity of lenalidomide combined with dexamethasone regimens in the treatment of RDD among adult patients at our hospital.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| RD | Experimental | Drug: lenalidomide and dexamethasonelenalidomide and dexamethasone |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Histologically confirmed diagnosis of RDD
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Patients must have adequate renal, liver, and bone marrow function as defined by the following criteria:
- Absolute neutrophil count ≥1500 cells per mm3 Platelet count ≥100000 cells per mm3 Creatinine clearance [according to Cockcroft formula] ≥60 mL/min. Aspartate aminotransferase and alanine aminotransferase ≤2·5×upper limit of normal [ULN], and total bilirubin ≤2·5×ULN; or ≤10×ULN in the case of known liver involvement by RDD.
Key exclusion criteria (8 listed)
- Patients had concurrent malignancies.
- History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.
- Women who were pregnant or of childbearing potential.
- Known HIV seropositive, active hepatitis C infection, and/or hepatitis B (defined as HCV RNA≥1000 copies or HBV DNA ≥1000 copies at screening).
- Major surgical procedure within 28 days prior to the first dose of study treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| lenalidomide and dexamethasonelenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22 | Drug | RD |
Primary outcome
Event-free survival
Time frame: the duration from initiation of treatment to the date of first documented event or date of death from any cause, whichever come first, assessed up to 5 years
Events were defined as a poor response to RD, reactivation after RD therapy and death from any cause.
2 secondary outcomes
Overall response rate
Time frame: on 12 months
Overall survival
Time frame: the duration from initiation of RD treatment to the date of death or last follow-up, assessed up to 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2021.
- Derived from this study: PubMed 39022796Chang L, Lang M, Liu T, Lin H, Liu ZZ, Cai H, Zhou DB, Cao XX. Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study. EClinicalMedicine. 2024 Jun 21;73:102685. doi: 10.1016/j.eclinm.2024.102685. eCollection 2024 Jul.
Related trials for Rosai-Dorfman Disease
RecruitingObservational study
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Erdheim-Chester Disease
RecruitingPhase 2
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
RecruitingPhase 2
Mirdametinib in Histiocytic Disorders
Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG)
RecruitingObservational study
Histiocytic Disorder Follow-up Study
Histiocytosis, Langerhans Cell Histiocytosis
Active, not recruitingObservational study
A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
Histiocytosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dao-bin Zhou study chair
Peking Union Medical College Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing lenalidomide and dexamethasone in people with Rosai-Dorfman Disease, run by Peking Union Medical College Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Xinxin Cao (18618315968, caoxinxin@pumch.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Event-free survival (time frame: the duration from initiation of treatment to the date of first documented event or date of death from any cause, whichever come first, assessed up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04924647, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2021.